Free Trial
NASDAQ:GRCE

Grace Therapeutics Q4 2025 Earnings Report

Grace Therapeutics logo
$3.00 +0.07 (+2.39%)
As of 06/24/2025 04:00 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, June 23, 2025
Conference Call Time
7:00AM ET

Grace Therapeutics Earnings Headlines

Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
Grace Therapeutics (GRCE) to Release Earnings on Friday
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat